MX2023013274A - Composiciones que incluyen potenciadores de tratamientos conjugados. - Google Patents

Composiciones que incluyen potenciadores de tratamientos conjugados.

Info

Publication number
MX2023013274A
MX2023013274A MX2023013274A MX2023013274A MX2023013274A MX 2023013274 A MX2023013274 A MX 2023013274A MX 2023013274 A MX2023013274 A MX 2023013274A MX 2023013274 A MX2023013274 A MX 2023013274A MX 2023013274 A MX2023013274 A MX 2023013274A
Authority
MX
Mexico
Prior art keywords
compositions including
including conjugated
enhancers
therapy
moiety
Prior art date
Application number
MX2023013274A
Other languages
English (en)
Spanish (es)
Inventor
Wieslaw Kazmierski
Richard Pracitto
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2023013274A publication Critical patent/MX2023013274A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023013274A 2021-05-17 2022-05-17 Composiciones que incluyen potenciadores de tratamientos conjugados. MX2023013274A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163189503P 2021-05-17 2021-05-17
PCT/US2022/029533 WO2022245757A1 (en) 2021-05-17 2022-05-17 Compositions including conjugated therapy enhancers

Publications (1)

Publication Number Publication Date
MX2023013274A true MX2023013274A (es) 2023-11-30

Family

ID=84140038

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013274A MX2023013274A (es) 2021-05-17 2022-05-17 Composiciones que incluyen potenciadores de tratamientos conjugados.

Country Status (12)

Country Link
US (1) US20240238436A1 (enExample)
EP (1) EP4351658A4 (enExample)
JP (1) JP2024519031A (enExample)
KR (1) KR20240012376A (enExample)
CN (1) CN117295527A (enExample)
AU (1) AU2022277840A1 (enExample)
BR (1) BR112023023506A2 (enExample)
CA (1) CA3219475A1 (enExample)
IL (1) IL307746A (enExample)
MX (1) MX2023013274A (enExample)
PH (1) PH12023553152A1 (enExample)
WO (1) WO2022245757A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026150353A2 (en) 2025-01-11 2026-07-16 Biohaven Therapeutics Ltd. Antibody-drug conjugates for delivering cytotoxic agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017139329A1 (en) * 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity lables
SG11202000628XA (en) * 2017-07-26 2020-02-27 Kleo Pharmaceuticals Inc Universal abt compounds and uses thereof
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
CN120865350A (zh) * 2019-01-23 2025-10-31 阿比蒂斯有限公司 用于制备抗体-载荷部分偶联物的化合物及其用途
AU2020234394B2 (en) * 2019-03-08 2024-02-15 AbTis Co., Ltd. Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof
KR20220103986A (ko) * 2019-11-18 2022-07-25 클레오 파마슈티컬스 인코포레이티드 지정 접합 기술
EP4069311A1 (en) * 2019-12-03 2022-10-12 Debiopharm Research & Manufacturing SA Reactive conjugates
WO2022078566A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
JPWO2022080385A1 (enExample) * 2020-10-13 2022-04-21
WO2022192478A1 (en) * 2021-03-10 2022-09-15 Biohaven Therapeutics Ltd. Bifunctional degraders of galactose-deficient immunoglobulins
IL307799A (en) * 2021-05-17 2023-12-01 Biohaven Therapeutics Ltd Agents for targeted coupling techniques and conjugated products
EP4340859A4 (en) * 2021-05-19 2025-07-02 Biohaven Therapeutics Ltd ANTIBODY-DRUG CONJUGATES USING COUPLING TECHNOLOGY TO DELIVER CYTOTOXIC AGENTS
WO2023043861A2 (en) * 2021-09-16 2023-03-23 Biohaven Therapeutics Ltd. Conjugated antibodies for treating diseases

Also Published As

Publication number Publication date
AU2022277840A9 (en) 2023-12-14
CN117295527A (zh) 2023-12-26
AU2022277840A1 (en) 2023-11-30
WO2022245757A1 (en) 2022-11-24
EP4351658A4 (en) 2026-04-15
JP2024519031A (ja) 2024-05-08
CA3219475A1 (en) 2022-11-24
PH12023553152A1 (en) 2024-03-11
EP4351658A1 (en) 2024-04-17
US20240238436A1 (en) 2024-07-18
KR20240012376A (ko) 2024-01-29
IL307746A (en) 2023-12-01
BR112023023506A2 (pt) 2024-01-30

Similar Documents

Publication Publication Date Title
CL2024003681A1 (es) Conjugado de anticuerpo anti-b7h3-fármaco y uso del mismo
PE20241582A1 (es) Anticuerpos lrrc15 y conjugaddos de los mismos
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
EA202091135A1 (ru) Гидрофильные линкеры для конъюгатов антитело-лекарственное средство
CL2019002178A1 (es) Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t.
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
BR112022006001A2 (pt) Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
BR112021024810A2 (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas
BR112018077362A2 (pt) conjugados para edição de superfície de célula-alvo
BR112022007719A2 (pt) Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
BR112013031028A2 (pt) conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
BR112021025034A2 (pt) Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado
WO2023012516A3 (en) Compositions and methods related to blood-brain barrier penetration
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
PE20231105A1 (es) Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso
CL2023002775A1 (es) Conjugados de amatoxina y anticuerpo específicos de linfocitos b
PE20240368A1 (es) Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos
BR112022017574A2 (pt) Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna
CL2023001509A1 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
CL2023001269A1 (es) Construcción polipeptídica que se une a cd3; composiciòn farmacéutica; y su uso.
PH12023553152A1 (en) Compositions including conjugated therapy enhancers
BR112022009942A2 (pt) Derivados de 1,2,4-oxadiazol como agonistas do receptor x do fígado
PE20131328A1 (es) Composiciones de anticuerpo anti-vegfr-3
CO2023010985A2 (es) Composiciones adhesivas que comprenden adhesivos de base biológica a partir de recursos renovables, y su uso para la fabricación de madera contrachapada